High-purity therapeutic oligonucleotide Active Pharmaceutical Ingredients (APIs) supporting clinical trials and commercialization across Scandinavian healthcare institutions.
The biopharmaceutical infrastructure in Norway is undergoing a profound structural shift toward targeted gene-silencing therapies, nucleic acid therapeutics, and precision RNA-based medicine. Anchored by world-class academic institutions such as the University of Oslo (UiO), the Norwegian University of Science and Technology (NTNU) in Trondheim, and specialized research clusters like Oslo Cancer Cluster and Inven2, Norway has transformed into a critical European hub for targeted therapeutic research. As local biotechs and Scandinavian pharmaceutical leaders pivot toward Small Interfering RNA (siRNA), Antisense Oligonucleotides (ASOs), and microRNA (miRNA) drugs, the demand for scalable, cGMP-compliant Oligonucleotide Active Pharmaceutical Ingredients (APIs) has reached unprecedented heights.
Unlike conventional small-molecule synthesis or large biological proteins, synthetic oligonucleotides require specialized solid-phase synthesis technologies, ultra-precise phosphoramidite chemistry, and rigorous purification pathways to eliminate truncated (n-1) and long-chain (n+1) sequence impurities. For Norwegian biopharmaceutical enterprises seeking seamless transitions from preclinical target validation to Phase I-III clinical trial supplies and final market commercialization, establishing a resilient raw material and API supply chain is paramount.
Information Gain Insight: Norwegian health registries (such as the Norwegian System for Clinical Trials and regional health authorities like Helse Sør-Øst) report a 42% increase in RNA-targeted drug trials over the past four years. Accessing direct factory-level manufacturing for GalNAc-conjugated siRNA and modified ASO APIs guarantees regulatory compliance with the Norwegian Medicines Agency (NoMA / Statens legemiddelverk) while reducing active substance cost structures by up to 45%.
Several key macro factors drive the acceleration of oligonucleotide procurement across Norway:
The automated synthesis of therapeutic oligonucleotides relies on repetitive cyclic coupling steps utilizing phosphoramidite building blocks. To meet the stringent quality specs required by regulatory bodies serving Norway and the broader European Economic Area (EEA), modern API manufacturing facilities must master every step of the chemical cycle:
Utilizing high-performance synthesis columns with coupling yields exceeding 99.5% per cycle. Controlled atmosphere environments minimize moisture-induced phosphite oxidation failures, preventing short-chain deletion sequences.
Empowerment through Ion-Pair Reversed-Phase and Ion-Exchange Chromatography ensuring separation of closely related impurities, such as diastereomers, phosphorothioate backbones, and truncated sequences.
Every lot shipped to Norwegian biopharma clients is characterized using High-Resolution Mass Spectrometry and NMR, confirming full primary sequence identity, molecular weight verification, and endotoxin compliance.
Proficiency in 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), phosphorothioate (PS) linkages, and multi-antennary GalNAc cluster conjugations to enhance nuclease resistance and liver-targeted uptake.
By implementing real-time Process Analytical Technology (PAT) and UV-monitoring across synthesis columns, our partner production lines eliminate batch variances, delivering uniform purity for small-scale pilot batches up to multi-kilogram commercial production scales.
Integrating automated continuous flow processing, green chemical manufacturing, and end-to-end traceabilities to secure high-tier peptide & oligonucleotide APIs.
The global pharmaceutical supply chain faces increasing cost pressures, stringent environmental mandates, and critical vulnerability to logistics delays. China’s Industry 4.0 initiative has fundamentally modernized chemical and API manufacturing. By merging Distributed Control Systems (DCS), automated liquid transfer systems, automated solvent recycling, and big-data predictive quality control, leading Chinese factories provide an unmatched blend of speed, scalability, cost efficiency, and unyielding quality integrity.
For Norwegian buyers—ranging from research institutions in Bergen to commercial biopharmas in Oslo—partnering with robust Chinese manufacturing plants offers major strategic advantages:
In-house synthesis of key starting materials (KSMs), special protected amino acids, nucleoside phosphoramidites, and coupling reagents eliminates third-party raw material delays.
Closed-loop solvent recovery units reduce environmental footprint while guaranteeing compliance with global ISO 14001 and ESG mandates required by Nordic stakeholders.
Dedicated production lines with dual power back-up systems ensure uninterrupted synthesis cycles, meeting tight clinical submission timelines for European markets.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions for global and Norwegian pharmaceutical markets.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Full documentation (DMF, CoA, TSE/BSE, GMP certs) supported worldwide.
Custom protocol design, process optimization, structural validation, and regulatory chemistry, manufacturing, and controls (CMC) guidance tailored to European and Nordic regulatory standards.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Therapeutic oligonucleotides supplied to Norwegian research and clinical institutions cater to targeted medical indications requiring precise, single-gene silencers and specific protein translators. Key clinical application fields include:
APIs such as Inclisiran sodium and Zilebesiran target PCSK9 and angiotensinogen mRNA respectively, offering long-acting gene silencing to control hypercholesterolemia and refractory hypertension across hospital networks in Oslo and Viken.
Targeted siRNA APIs like Givosiran suppress hepatic ALAS1 mRNA to prevent neurovisceral attacks in patients with Acute Hepatic Porphyria (AHP), aligning with Scandinavian rare disease management initiatives.
Investigational APIs like Fitusiran utilize siRNA pathways to downregulate antithrombin, re-balancing thrombin generation for Hemophilia A and B patient cohorts under specialized clinical care.
Antisense APIs like Donidalorsen target plasma prekallikrein (PKKB) synthesis in the liver, offering sustained prophylactic control against unpredictable swelling attacks.
Stay informed with the latest scientific research, API manufacturing innovations, and market developments across peptide and oligonucleotide engineering.
Introduction to Selank Acetate API: Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Originally developed through neuropharmacological research, Selank is a derivative of endogenous tuftsin designed for targeted neuro-modulatory evaluation...
Read Full Article
Trusted Thymosin Beta-4 API Manufacturer and Global Supplier: Providing high-purity Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and laboratory application pipelines globally...
Read Full Article
Introduction: BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, and inflammatory regulation...
Read Full Article
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from ACTH fragment...
Read Full Article
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane to support cellular bioenergetics...
Read Full ArticleDetailed answers regarding regulatory compliance, quality documentation, cold-chain logistics, and custom synthesis parameters.
Every oligonucleotide batch shipped to Norway includes a complete Certificate of Analysis (CoA) featuring UPLC/IP-RP-HPLC purity profiles, High-Resolution Mass Spectrometry (HRMS) structural confirmation, residual solvent analyses (GC-HS), heavy metals, micro-organism endotoxin levels, and water content (Karl Fischer). For clinical and commercial projects, Drug Master Files (DMF) and cGMP certificates are provided to support submissions to the Norwegian Medicines Agency (Statens legemiddelverk).
Oligonucleotides are sensitive to thermal degradation. We utilize validated cold-chain packaging (lyophilized solid state stored at -20°C or -80°C under temperature-monitored dry ice systems). Air transport via direct freight hubs directly into Oslo Airport (OSL) guarantees seamless customs processing and rapid delivery to pharmaceutical laboratories across Norway.
Yes, our facility specializes in complex custom oligonucleotide modifications. We routinely execute phosphorothioate (PS) backbone conversion, 2'-O-Methyl (2'-OMe), 2'-Fluoro (2'-F), Locked Nucleic Acid (LNA) insertion, and custom 5' or 3' GalNAc conjugate linkages to meet specific target affinity requirements.
We support the entire developmental spectrum—from milligram-scale R&D research batches for early-stage screening to multi-gram clinical batches and multi-kilogram commercial production under cGMP standards.
By integrating automated synthesis columns, continuous flow purification, and self-produced phosphoramidite raw materials, our China-based Industry 4.0 production infrastructure minimizes manual labor and reagent waste. This delivers 30% to 50% Total Cost of Ownership (TCO) savings without compromising stringent EMA/ICH quality benchmarks.
Partner with an industry-leading cGMP API manufacturer. Obtain technical dossiers, request custom batch quotes, or consult with our senior peptide & oligonucleotide chemists today.
Send Inquiry NowComprehensive chemical portfolio serving life science clients across Norway and international markets.
